THERAPY DOSSIER · th-8091030ae140

Fas siRNA formulated with the liver-specific delivery system DBTC (DBTC/siRNA(Fas))

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25601293 ↗2015Reported benefit

Liver-specific Fas silencing prevents galactosamine/lipopolysaccharide-induced liver injury.

MouseEndotoxin/LPSC57BL/6Male48 h before galactosamine/lipopolysaccharide challenge

Model: Galactosamine/lipopolysaccharide-induced acute liver failure

DBTC/siRNA(Fas) reduced hepatic but not extrahepatic Fas expression, improved hepatic perfusion, reduced hepatocellular death and increased survival after galactosamine/lipopolysaccharide. TNF-alpha mRNA fell markedly while plasma IL-6 was unchanged, so protection from inflammation was only partial.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…